Pfizer
1Q Revenues: $12.9 billion (+1%)
1Q Earnings: $3.6 billion (+14%)
Comments: Innovative Health sales were $7.8 billion in the quarter, up 6% driven by continued growth from key brands including Ibrance, Eliquis and Xeljanz. Global operational revenue growth for Ibrance, Eliquis and Xeljanz was 35%, 30% and 29%, respectively. This growth was partially offset by the loss of exclusivity of Viagra in the U.S. Also, in the U.S., Prevnar 13 revenues were down 12%, primarily due to lower government purchases compared to 1Q17. Essential Health sales were down 5% to $5.1 billion impacted primarily by a 15% operational decline from the Sterile Injectable Pharmaceuticals (SIP) portfolio, due to continued legacy Hospira product shortages in the U.S. Pfizer completed the sale of its global infusion therapy net assets, Hospira Infusion Systems.